Led by the Digital Health & Care Innovation Centre (DHI), the AIM4ALL (Access to Innovative Medicines for All) initiative is redefining how modern medicines are evaluated, accessed, and reimbursed across health systems.
As Scotland’s national innovation centre for digital health and care, DHI plays a pivotal role in coordinating partners, developing data infrastructure, and enabling collaboration between health systems, industry, and researchers to accelerate access to innovative therapies.
AIM4ALL is building a trusted, confidential, and multi-jurisdictional “Living Lab” research environment that brings together real-world health system and citizen-generated outcomes data. This approach is designed to support the full lifecycle of medicine development from clinical trials through to post-marketing studies and helps address long-standing data landscape challenges.
By enabling the secure collection and use of standardised data across jurisdictions, AIM4ALL can support manufacturers, health technology assessment (HTA) organisations, and the testing of innovative pricing and reimbursement models that can improve affordability and access to high-value, innovative therapies.
The project was developed in response to the widening gap between 21st-century medical innovation and 20th-century evidence and procurement models. As the number of potentially life-transforming but high-cost medicines grow, often targeting small patient populations with limited or emergent evidence, traditional approaches to pricing and approval have become increasingly strained. AIM4ALL aims to replace adversarial pricing negotiations with collaborative, data-driven partnerships between health systems and manufacturers.
DHI successfully led Phase 1 of the programme, completed in early 2024, which demonstrated strong stakeholder alignment and delivered a scalable proof-of-concept (PoC) data management platform. By standardising data collection across treatment pathways and integrating citizen-generated data with formal clinical data, real-world data can be captured to understand the patient experience better.
Phase 2 (2025-2026) will see DHI and its partners seek to establish robust but streamlined governance frameworks supporting the deployment of the PoC into a live clinical environment and identify initial outcomes-based contracting (OBC) use cases. Subsequent phases will focus on implementing full OBC arrangements (2027) and scaling the model across multiple jurisdictions thereafter…
AIM4ALL is supported by the Life Sciences Industry Leadership Group’s Digital and Data Subgroup and is led in Scotland by DHI, working in close partnership with Research Data Scotland. Funding contributions have come from Scottish Enterprise, Innovate UK, and the Cell & Gene Therapy Catapult.
AIM4ALL is extending its reach beyond Scotland, engaging jurisdictions such as Wales, England, Denmark, Ireland, Canada, and the Netherlands. This expansion is laying the foundation for a robust multi-jurisdictional Living Lab network, enabling shared learning, scalable deployment, and the creation of innovative reimbursement models that link payment to patient outcomes over time.
In summary, AIM4ALL represents a paradigm shift in the way health systems engage with innovation. By leveraging real-world data and fostering collaboration across sectors and borders, it is helping to create a more sustainable, equitable model for healthcare innovation that benefits citizens, clinicians, and industry alike.